 
 
Disclaimer: The below article is sponsored, and the views in it do not represent those of ZyCrypto. Readers should conduct independent research before taking any actions related to the project mentioned in this piece. This article should not be regarded as investment advice.
Lite Strategy, Inc. (NASDAQ: LITS) has announced its financial results for the first quarter of fiscal year 2026. This marks a pivotal period driven by the implementation of its $100 million Litecoin-focused treasury strategy and the company’s shift into more active capital market operations.
The company, which recently rebranded from MEI Pharma, now stands as the first publicly traded entity in the United States to hold institutional exposure to Litecoin at scale. By September 30, 2025, Lite Strategy had accumulated 929,548 LTC, positioning itself at the forefront of corporate participation in the Litecoin ecosystem.
A Transformative Quarter for the Company
Commenting on the project, Board Member Charlie Lee stated:
“Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus. We recently celebrated Litecoin’s 14th anniversary and its unblemished track record of reliability and uptime. LITS provides investors with the only US publicly traded company to gain institutional exposure to Litecoin, both for portfolio diversification and long-term value.”
 
Chief Executive and Financial Officer Jay File highlighted that the company’s progress is the culmination of strategic decisions made throughout the previous fiscal year. He pointed out that the sale of the clinical asset ME-344, now known as WE-868, marked a major step in reshaping the company’s direction. Additionally, the company’s $100 million PIPE financing, completed in July 2025, laid the groundwork for launching its digital asset treasury strategy in the first quarter of FY 2026.
Key Milestones and Strategic Moves
Throughout the quarter, Lite Strategy initiated the deployment of its $100 million treasury program, establishing Litecoin as its primary reserve asset. A partnership with GSR supported this strategic shift. This prominent digital asset investment firm now guides the company’s governance, execution, and market positioning in the digital asset space.
Lite Strategy also expanded its leadership team with the appointment of Charlie Lee and Joshua Riezman, GSR’s U.S. Chief Strategy Officer, to its board of directors. These additions were accompanied by a full corporate rebrand, including the transition from MEI Pharma to Lite Strategy, a change of its NASDAQ ticker symbol to LITS, and the introduction of a new brand identity and website.
In October, the company advanced from the asset accumulation phase into active capital market participation by announcing a $25 million share repurchase program. This move underscores the company’s ability to leverage its nearly one million Litecoin treasury—an advantage that distinguishes it from passive investment vehicles such as exchange-traded funds.
Clinical Portfolio Review and Capital Program Outlook
Jay File also confirmed that Lite Strategy is continuing to evaluate its remaining clinical assets. Pre-clinical activity with voruciclib in non-oncology indications is underway as part of efforts to identify licensing opportunities. The company is likewise considering strategic options for zandelisib, including partnerships or potential sale.
File further noted that the recently approved stock buyback program will be used selectively as the company works to narrow the gap between its trading price and its net asset value.
About Lite Strategy, Inc.
Lite Strategy, Inc. (NASDAQ: LITS), formerly known for its pharmaceutical research portfolio, the company now operates with a renewed focus on digital asset treasury management, blockchain innovation, and capital markets strategy, developed in collaboration with leading partners in finance and technology